AIMS/HYPOTHESIS: Our aims were to investigate the concentrations and prevalence of autoantibodies against the Mr 65.000 isoform of glutamate decarboxylase (GAD65) and the tyrosine phosphatase-like protein (IA-2) in adults and to test the hypothesis that GAD65 and IA-2 autoantibodies in a regional population are related to abnormal oral glucose tolerance. METHODS: We analysed serum from 2157 Swedish subjects aged either 30, 40, 50 or 60 years old who, in 1988-1992, participated in the Västerbotten County Health Project and were subjected to the World Health Organisation (WHO) standard oral glucose tolerance test at entry into the study. RESULTS: We found 23 of 2157 (1.1%) and 17 of 2152 (0.8%) subjects exceeded the 99th centile of GAD65 autoantibody index and IA-2 autoantibody index, respectively. In 18 subjects with diabetic oral glucose tolerance test, GAD65 autoantibody concentrations were higher than in those with normal oral glucose tolerance test (p = 0.02). Subjects with IGT (n = 185) [corrected] and diabetes (n = 18), i.e. abnormal OGTT (n = 203) [corrected], had higher GAD65Ab [corrected] index compared with those with normal OGTT (p = 0.026) [corrected]. A stepwise multiple logistic regression test showed that the odds ratios for subjects in the highest BMI group to exceed the 95th or 99th GAD65 autoantibody centile were 3.6 (CI 1.4-8.9) and 17.6 (CI 2.6-121.6), respectively. CONCLUSION/ INTERPRETATION: GAD65 and IA-2 autoantibodies, are associated with impaired or diabetic glucose tolerance in an adult regional population. This observation together with the association between GAD65 autoantibody concentrations and body mass index indicate a possible relation between islet autoimmunity and beta-cell function abnormalities with obesity and insulin resistance.
AIMS/HYPOTHESIS: Our aims were to investigate the concentrations and prevalence of autoantibodies against the Mr 65.000 isoform of glutamate decarboxylase (GAD65) and the tyrosine phosphatase-like protein (IA-2) in adults and to test the hypothesis that GAD65 and IA-2 autoantibodies in a regional population are related to abnormal oral glucose tolerance. METHODS: We analysed serum from 2157 Swedish subjects aged either 30, 40, 50 or 60 years old who, in 1988-1992, participated in the Västerbotten County Health Project and were subjected to the World Health Organisation (WHO) standard oral glucose tolerance test at entry into the study. RESULTS: We found 23 of 2157 (1.1%) and 17 of 2152 (0.8%) subjects exceeded the 99th centile of GAD65 autoantibody index and IA-2 autoantibody index, respectively. In 18 subjects with diabetic oral glucose tolerance test, GAD65 autoantibody concentrations were higher than in those with normal oral glucose tolerance test (p = 0.02). Subjects with IGT (n = 185) [corrected] and diabetes (n = 18), i.e. abnormal OGTT (n = 203) [corrected], had higher GAD65Ab [corrected] index compared with those with normal OGTT (p = 0.026) [corrected]. A stepwise multiple logistic regression test showed that the odds ratios for subjects in the highest BMI group to exceed the 95th or 99th GAD65 autoantibody centile were 3.6 (CI 1.4-8.9) and 17.6 (CI 2.6-121.6), respectively. CONCLUSION/ INTERPRETATION:GAD65 and IA-2 autoantibodies, are associated with impaired or diabetic glucose tolerance in an adult regional population. This observation together with the association between GAD65 autoantibody concentrations and body mass index indicate a possible relation between islet autoimmunity and beta-cell function abnormalities with obesity and insulin resistance.
Authors: Ingrid M Libman; E Barinas-Mitchell; S Marcovina; F Bacha; T Hannon; H Tfayli; S J Lee; S Bansal; R Robertson; S Arslanian Journal: Pediatr Diabetes Date: 2010-09-07 Impact factor: 4.866
Authors: C S Hampe; J R Radtke; A Wester; A Carlsson; E Cedervall; B Jönsson; S A Ivarsson; H Elding Larsson; K Larsson; B Lindberg; J Neiderud; O Rolandsson; Å Lernmark Journal: Diabet Med Date: 2018-12-28 Impact factor: 4.359
Authors: Rebecka Hjort; Josefin E Löfvenborg; Emma Ahlqvist; Lars Alfredsson; Tomas Andersson; Valdemar Grill; Leif Groop; Elin P Sørgjerd; Tiinamaija Tuomi; Bjørn Olav Åsvold; Sofia Carlsson Journal: J Clin Endocrinol Metab Date: 2019-10-01 Impact factor: 5.958
Authors: K H Mortensen; L Cleemann; B E Hjerrild; E Nexo; H Locht; E M Jeppesen; C H Gravholt Journal: Clin Exp Immunol Date: 2009-02-26 Impact factor: 4.330
Authors: Mai Lin; Angelo Lubag; Michael J McGuire; Serguei Y Seliounine; Edward N Tsyganov; Peter P Antich; A Dean Sherry; Kathlynn C Brown; Xiankai Sun Journal: Front Biosci Date: 2008-05-01
Authors: L M Shulman; C S Hampe; A Ben-Haroush; Y Perepliotchikov; F Vaziri-Sani; S Israel; K Miller; H Bin; B Kaplan; Z Laron Journal: Diabet Med Date: 2014-02-25 Impact factor: 4.359
Authors: D Luo; L K Gilliam; C Greenbaum; L Bekris; C S Hampe; T Daniels; W Richter; S M Marcovina; O Rolandsson; M Landin-Olsson; I Kockum; A Lernmark Journal: Diabetologia Date: 2004-09-08 Impact factor: 10.122